Abstract: In its several embodiments, this invention discloses a pharmaceutical formulation comprising at least one antineoplastic agent or a pharmaceutically acceptable salt thereof, and at least one dissolution enhancing agent sufficient to substantially dissolve said at least one antineoplastic agent in at least one aqueous diluent, wherein said dissolution enhancing agent is urea, L-histidine, L-threonine, L-asparagine, L-serine, L-glutamine or mixtures thereof; a lyophilized powder comprising said pharmaceutical formulation, and articles of manufacture thereof.
Type:
Grant
Filed:
January 13, 2006
Date of Patent:
March 9, 2010
Assignee:
Schering Corporation
Inventors:
Sydney Ugwu, Vinay Radhakrishnan, Peter M. Ihnat, Leonore C. Witchey-Lakshmanan
Abstract: The problem of the present invention is to provide a preventive and/or therapeutic agent for diabetes and/or complications of diabetes based on the novel mode of action. The protease-inhibiting compound according to the present invention is a compound represented by the general formula (I) [wherein all the symbols have the same meanings as described in the specification], its salt or solvate, or a prodrug thereof, is useful as a preventive and/or therapeutic agent for diabetes and/or complications of diabetes.
Abstract: The present invention provides pharmaceutical compositions for the prevention or treatment of lipid metabolism disorders. The pharmaceutical compositions comprising, as an active ingredient, (2S)-2-benzl-3-(cis-hexahydro-2-isoindolinylcarbonyl)propionic aid (generic name: mitiglinide) or a pharmaceutically acceptable salt thereof, or a hydrate thereof exert remarkable lipid metabolism improving effect, and are useful for, for example, hyperlipidemia such as hypertriglyceridemia of diabetic patients or the like.
Abstract: A composition comprising, per liter of aqueous solution, from 30 to 350 g polyethylene glycol, from 3 to 20 g of an ascorbic acid component selected form the group consisting of ascorbic acid, a salt of ascorbic acid, or a mixture thereof, an alkali metal or alkaline earth metal sulphate, preferably from 1 to 15 g thereof, and optionally one or more electrolytes selected from sodium chloride, potassium chloride, and sodium hydrogen carbonate, and preferably also comprising flavorings, is effective in cleansing the gut in preparation for a endoscopy, especially colonoscopy. It is safer than conventional sodium phosphate-based gut cleansing compositions, and hence can be used for patients who would be at risk with sodium phosphate-based compositions, and is better tolerated than conventional PEG-based compositions, leading to better patient compliance and enabling effective out-patient use.
Type:
Grant
Filed:
December 8, 2006
Date of Patent:
February 9, 2010
Assignee:
Norgine BV
Inventors:
Norman Barras, Ian David Cox, Alex Ungar, Marc Halphen
Abstract: Methods for using (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines are disclosed herein to treat rho kinase-mediated diseases or rho kinase-mediated conditions, including controlling intraocular pressure and treating glaucoma, are disclosed. Ophthalmic pharmaceutical compositions useful in the treatment of eye diseases such as glaucoma, and additionally useful for controlling intraocular pressure, the compositions comprising an effective amount of (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines, are disclosed herein.
Type:
Grant
Filed:
December 19, 2006
Date of Patent:
February 2, 2010
Assignee:
Alcon Research, Ltd.
Inventors:
Mark R. Hellberg, Najam A. Sharif, Jesse A. May, Andrew Rusinko, Hwang-Hsing Chen
Abstract: Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.
Type:
Grant
Filed:
October 28, 2003
Date of Patent:
January 12, 2010
Assignee:
Wellstat Therapeutics Corporation
Inventors:
Kirvin L. Hodge, Shalini Sharma, Reid W. von Borstel, Stephen D. Wolpe
Abstract: Stabilized pharmaceutical preparations containing a drug in which is sensitive to a low pH environment, such as pravastatin are disclosed in which pravastatin degradations is prevented with a buffering agent. The basic excipient enhances storage stability.
Type:
Grant
Filed:
June 5, 2002
Date of Patent:
January 5, 2010
Assignee:
Andrx Pharmaceuticals, Inc.
Inventors:
Boyong Li, Avinash Nangia, Aaron Dely, David Wong
Abstract: A medicinal composition which comprises an insulin resistance-improving drug and vitamin B1 or derivative thereof. In this medicinal composition, the side effects of the insulin resistance-improving drug such as edema, heart enlargement, anemia, etc. are prevented by using vitamin B1 or its derivative together. It is usable as a remedy for diabetes, a remedy for lifestyle related diseases, an anti-tumor agent, an anti-rheumatoid drug and so on.
Abstract: This invention relates to use of a pyrazole-derived compound that is an antagonist of cannabinoid CB1 receptors, alone or in combination with another active ingredient, for preparing medicinal products that are of use in the prevention and treatment of kidney diseases.
Type:
Grant
Filed:
August 2, 2007
Date of Patent:
November 24, 2009
Assignee:
sanofi-aventis
Inventors:
Mohammed Bensaid, Jean-Marc Herbert, Philip Janiak
Abstract: The present invention relates to the use of certain dialkyl fumarates for the preparation of pharmaceutical preparations for use in transplantation medicine or for the therapy of autoimmune diseases and said compositions in the form of micro-tablets or pellets. For this purpose, the dialkyl fumarates may also be used in combination with conventional preparations used in transplantation medicine and immunosuppressive agents, especially cyclosporines.
Abstract: The present invention relates to the use of certain dialkyl fumarates for the preparation of pharmaceutical preparations for use in transplantation medicine or for the therapy of autoimmune diseases and said compositions in the form of micro-tablets or pellets. For this purpose, the dialkyl fumarates may also be used in combination with conventional preparations used in transplantation medicine and immunosuppressive agents, especially cyclosporines.
Abstract: The present invention has an object to provide an antibacterial aqueous pharmaceutical composition and an aqueous pharmaceutical composition which have a sufficiently low gelation temperature even when new quinolone antibacterial agents such as ofloxacin as the active ingredient and can be retained at the administration site for a long time by virtue of rapid viscosity increase after administration in spite of their being liquid at administration and thereby attain high availability of pharmaceutical agent. The present invention relates to an antibacterial aqueous pharmaceutical composition which comprises: 2.8 to 4 w/v % of methylcellulose, the 2 w/v % aqueous solution of which has a viscosity of 12 mPa·s or below at 20° C.; 1.5 to 2.3 w/v % of citric acid; 2 to 4 w/v % of polyethylene glycol; and 0.1 to 0.5 w/v % of ofloxacin.
Abstract: Creatine oral supplementation using creatine hydrochloride salt, that may be added to a liquid or other beverage, or may be also used as an additive to solid oral dosages, or as a supplement, and which may be consumed by the athlete, or other party looking for immediate supplementation of strength, and may be added as a supplement within feed to livestock, in the veterinary area.
Type:
Grant
Filed:
May 14, 2004
Date of Patent:
October 27, 2009
Assignee:
Board of Regents of the University of Nebraska
Inventors:
Donald W. Miller, Jonathan L. Vennerstrom, Mark C. Faulkner
Abstract: Abrasive compositions which include bioactive materials, such as bioactive glass and bioactive ceramics, which provide biological properties such as anti-inflammatory, anti-microbial, anti-oxidant effects, improved wound healing, and/or other beneficial effects are provided. Also provided are abrasive compositions comprising relatively non-toxic, bioinert glasses and ceramics which provide good abrasive effects, reduce or eliminate potentially harmful small particles; reduce or eliminate clogging of dermabrasion equipment; possess a relatively large surface area for applying coatings; and may be inexpensive and simple to make. Methods for abrading human or animal tissue, such as human skin, by contacting such tissue with these abrasive compositions is also provided.
Abstract: A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a angiotensin antagonist is herein disclosed and described.
Abstract: Androst-5-ene-3&bgr;,17&bgr; diol is used to treat or reduce the likelihood of acquiring osteoporosis or menopausal symptoms, or other diseases affected by estrogen receptor activity, and for conditions which respond well to DHEA treatment, but where a higher ratio of estrogenic to androgenic effects is desired. Combination therapies are included, as are kits and pharmaceutical compositions for providing the active ingredients of claimed methods and combinations.
Abstract: Novel carbocyclic compounds are described. The compounds generally comprise an acidic group, a basic group, a substituted amino or N-acyl and a group having an optionally hydroxylated alkane moiety. Pharmaceutical compositions comprising the inhibitors of the invention are also described. Methods of inhibiting neuraminidase in samples suspected of containing neuraminidase are also described. Antigenic materials, polymers, antibodies, conjugates of the compounds of the invention with labels, and assay methods for detecting neuraminidase activity are also described.
Type:
Grant
Filed:
June 6, 1995
Date of Patent:
February 2, 1999
Assignee:
Gilead Sciences, Inc.
Inventors:
Willard Lew, Choung U. Kim, Hongtao Liu, Matthew A. Williams
Abstract: A pharmaceutical preparation of antistress, stress-protective and nootropic effect contains an effective substance represented by an amino-acid glycine or its pharmaceutically acceptable salt.A method of prophylaxis and curing of stress states and also increasing mental workability consists in sublingually administering an effective amount of the preparation of patent protection sought.
Abstract: The present invention provides a method for treating or preventing certain metabolic disorders comprising the systemic administration of 3-guanidinopropionic acid.